Results 111 to 120 of about 744,838 (140)

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study. [PDF]

Orphanet J Rare Dis
Holida M, Linhart A, Longo N, Wallace E, Tøndel C, Hughes D, Warnock DG, Pisani A, Eyskens F, Deegan P, Feldt-Rasmussen U, Goker-Alpan O, Mehta A, Piotti G, Fichera V, Wang M, Chertkoff R, Waldek S, Wilcox WR, Bernat JA.   +19 more
europepmc   +1 more source

A rapid method to reduce drug interferences for antibody measurements in pegunigalsidase alfa-treated patients with Fabry disease. [PDF]

Front Immunol
Lenders M, Rudolph E, Rudnicki M, Cybulla M, Brand E.   +4 more
europepmc   +1 more source

Impaired motor unit profile in Fabry disease: A quantitative electrophysiological study. [PDF]

Clin Neurophysiol Pract
Gunduz A, Akkan Suzan A, Dinçer MT, Özcan ŞG, Seyahi N.   +4 more
europepmc   +1 more source

Expert Opinion on the Conceptual, Clinical, and Therapeutic Aspects of Fabry Nephropathy: A Nephrologists' Perspective.

Kidney Blood Press Res
Eren N, Turkmen K, Turgut F, Tokgoz B, Inci A, Seyahi N.   +5 more
europepmc   +1 more source

Prevalence and sociodemographic, clinical, and genetic characteristics of Fabry disease in north-central Chile, 2013-2023. [PDF]

Mol Genet Metab Rep
Royo Martínez S, Castillo-Montes M, Molt F, Cortes Rivera B, Ramírez-Santana M.   +4 more
europepmc   +1 more source

Bridging Biochemical and Clinical Disease Burden in Fabry Disease: A Comparative Analysis of Lyso-Gb3, MSSI, DS3, and FASTEX. [PDF]

Int J Mol Sci
Ozturk S, Akyol EMB.
europepmc   +1 more source

Cardiological aspects of Fabry disease: from diagnosis to therapeutic efficacy assessment. [PDF]

Orphanet J Rare Dis
Graziani F, Biagini E, Argirò A, Citro R, Iaccarino G, Lanzillo C, Monte I, Pieruzzi F, Zuchi C, Pieroni M.   +9 more
europepmc   +1 more source

Integrated Glyco-Analytical Strategy for Comprehensive Characterization of a Complex Therapeutic Glycoprotein: Fabrazyme. [PDF]

Int J Mol Sci
Afonin M, Novikova P, Vinalev A, Mesonzhnik N.   +3 more
europepmc   +1 more source

Impact of Proteinuria on Renal Outcomes in the BALANCE Trial. [PDF]

Kidney Int Rep
Wallace EL, Wanner C, Piotti G, Lee D, Koulinska I, Chertkoff R, Warnock DG, BALANCE Study Group.   +7 more
europepmc   +1 more source

Therapeutic landscape of Fabry disease: advances and challenges from classical strategies to emerging therapies. [PDF]

Front Med (Lausanne)
Zhang M, Wang C.
europepmc   +1 more source